Posted by Michael Wonder on 26 Dec 2021
SIGA announces Health Canada regulatory approval of oral TPOXX
1 December 2021 - SIGA Technologies today announced that Health Canada has approved oral Tpoxx (tecovirimat) as an extraordinary use new drug.
Specifically, Health Canada has authorised the use of oral Tpoxx for the treatment of human smallpox disease in adults and paediatric patients weighing at least 13 kg.
